Clinical trials: Hypertension, Essential
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Essential Hypertension
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
- Trial name
- NCT07282145
- Testing
- BCD101 Low Dose Liquid Formulation, BCD101 High Dose Liquid Formulation, BCD101 Low + High Dose Liquid Formulation
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bichedam Co., Ltd.
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and losartan alone in patients with essential hypertension inadequately controlled on losartan monotherapy.
- Trial name
- NCT00940680
- Testing
- Amlodipine plus Losartan, Losartan
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Essential Hypertension
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential…
- Trial name
- BENEFIT (NCT03847350)
- Where
- South Korea
- Volunteers
- 3,250 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Hypertension
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination treatment in patients with essential hypertension…
- Trial name
- NCT01828359
- Testing
- Amosartan® tab, Cozaar® plus pro tab
- Volunteers
- 199 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
Micardis® in Patients With Essential Hypertension
The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02187705
- Testing
- Telmisartan tablets
- Volunteers
- 1,688 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 \& 10 mg, and patients' compliance in the treatment of…
- Trial name
- BETTER (NCT05880056)
- Testing
- Nerkardou (5 mg) & (10 mg)
- Where
- Egypt
- Volunteers
- 406 people
- Sponsor
- Genuine Research Center, Egypt
Essential Hypertension
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts.
- Trial name
- NCT02062645
- Testing
- amlodipine/valsartan
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure.
- Trial name
- NCT01122251
- Testing
- Lercanidipine + Valsartan, Lercanidipine or Valsartan
- Where
- 2 sites in South Korea
- Volunteers
- 441 people
- Sponsor
- LG Life Sciences
Essential Hypertension, Dyslipidemia
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin…
- Trial name
- FIRST (NCT03156842)
- Testing
- Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02238262
- Testing
- Telmisartan
- Volunteers
- 2,318 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension
- Trial name
- NCT00487123
- Testing
- Valsartan+/- Hydrochlorothiazide
- Where
- Singapore
- Sponsor
- Novartis